[Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)].
Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T.
Ogiya D, et al. Among authors: chou t.
Rinsho Ketsueki. 2016;57(11):2311-2318. doi: 10.11406/rinketsu.57.2311.
Rinsho Ketsueki. 2016.
PMID: 27941278
Clinical Trial.
Japanese.